Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Special points of interest th Du op a ( Du e oh p ah ) January 12 2015 FDA approved the release of Duopa D UO P A w as ap p r o ved Used for the treatment of: Motor fluctuations in patients with b y th e F D A as an or p h a n advanced Parkinson's disease. Dosage: Enteral Suspension. d r u g , a d es i gn at ion Marketing Information from Manufacturer: gr an ted to p r od u ct s Duopa (Due oh pah) provides patients with the same active ingredients as orally-administered carbidopa and levodopa immediate release, but is delivered in a suspension that goes directly into the small intestine via a tube. "There is unmet need for treatment options for patients with advanced Parkinson's disease. As the disease advances, it can be difficult to control motor features," Dr. Olanow said in the company statement. "In clinical trials, Duopa was shown to significantly reduce the amount of off time (per 16 waking hours) advanced Parkinson's disease patients experienced.” Benefits and Concerns of the Drug: This drug is targeted for a limited number of Parkinson’s patients and its administration through an enteral tube further limits potential candidates for Duopa. Prior Authorization for coverage is suggested to assure only properly qualified and prepared patients receive coverage for the drug. Coverage Recommendations: These recommendations are available to IPC/EvergreenRx clients from their Account Manager or Clinical Pharmacist. in ten d ed for th e Please contact us with any questions or comments tr eatm en t o f r ar e d is e a se s. Gen er ic N am e car b id op a an d le vod op a T 636.614.1344 www.ipc-inc.com A Brown & Brown company